Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
22 hedge funds and large institutions have $5.27M invested in Talis Biomedical Corporation Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2.9% less ownership
Funds ownership: 43.76% → 40.86% (-2.9%)
9% less capital invested
Capital invested by funds: $5.76M → $5.27M (-$490K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$23.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$18.8K |
| 3 |
Renaissance Technologies
New York
|
+$6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.07K |
| 5 |
Morgan Stanley
New York
|
+$486 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$235K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$110K |
| 3 |
Mercer Global Advisors
Denver,
Colorado
|
-$39K |
| 4 |
Millennium Management
New York
|
-$34.9K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.17K |
TLIS Hedge Fund Activity: Q2 2023 in Review
22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q2 2023, worth a combined $5.27M — down 8.5% from $5.76M a quarter earlier.
Fund positioning in TLIS was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $23.7K. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $235K sold.
- 22 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $5.27M of Talis Biomedical Corporation Common Stock stock for Q2 2023, down 8.5% quarter-over-quarter.
- 3 funds opened new Talis Biomedical Corporation Common Stock positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q2 2023 was Two Sigma Securities, an estimated $23.7K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q2 2023 was ArrowMark Colorado Holdings, an estimated $235K sold.
Based on aggregated 13F filings for Q2 2023.